Formulation and Evaluation of Sustained Release Colon Targeted Mesalamine Tablet

For the treatment of a range of local diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer Colon-specific drug delivery systems (CDDS) are used. In addition, the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions. Colon targeted drug delivery system of Mesalamine tablets were prepared by using different formulae by direct compression method by using different concentration of Hydroxypropyl methyl cellulose (HPMC) and Ethyl Cellulose (EC). All the formulations of tablet (F1 to F6) were subjected for in vitro dissolution in 0.1 N HCL (pH 1.2) for suitability for colon specific drug delivery system. Tablets were evaluated for micrometric properties of granules, physical properties and drug content. F5 was optimized and subjected to coating based on evaluation results. The dissolution study of F5 revealed in simulated intestinal fluid release was 85.52% at the end of 6 h and was 101% at the end of 8 h. the studies confirmed that the designed formulation could be used potentially for colon delivery by controlling drug release in intestine.